NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/09/2024
Back to search
Official data from USPTO
TALLAC THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
TALLAC THERAPEUTICS
ST13
US500000090016459Class
5
Filing
90016459
Registration
7270000
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
53
Latest update
01/09/2024
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
06/23/2020
Registration date
01/09/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/09/2024
Last transaction
01/09/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
09/11/2023
First use in commerce
09/11/2023
Drawing code
4
Owner type
03
Owner location
SAN FRANCISCO, CA, US
Examiner
GULIANO, ROBERT
Law office
L50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
TALLAC THERAPEUTICS, INC.
Representatives
Jessica L. Rothstein GOODWIN PROCTER LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticals in the field of immune cell activation with toll-like receptor agonist antibody-conjugates (TRAAC)pharmaceuticals for the treatment and prevention of immune system related diseases and disordersinflammatory diseases and disordersautoimmune diseases and disorderscancer
Publications
History of USPTO decisions and trademark events.
53 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/09/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/07/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/06/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/15/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/14/2023
EX5G
SOU EXTENSION 5 GRANTED
11/14/2023
IUAF
USE AMENDMENT FILED
11/09/2023
EXT5
SOU EXTENSION 5 FILED
11/09/2023
EEXT
SOU TEAS EXTENSION RECEIVED
11/09/2023
EISU
TEAS STATEMENT OF USE RECEIVED
11/09/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/20/2023
EX4G
SOU EXTENSION 4 GRANTED
06/18/2023
EXT4
SOU EXTENSION 4 FILED
06/18/2023
EEXT
SOU TEAS EXTENSION RECEIVED
06/18/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/22/2022
EX3G
SOU EXTENSION 3 GRANTED
12/20/2022
EXT3
SOU EXTENSION 3 FILED
12/20/2022
EEXT
SOU TEAS EXTENSION RECEIVED
12/20/2022
DOCK
ASSIGNED TO EXAMINER
11/21/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/21/2022
EX2G
SOU EXTENSION 2 GRANTED
06/19/2022
EXT2
SOU EXTENSION 2 FILED
06/19/2022
EEXT
SOU TEAS EXTENSION RECEIVED
06/19/2022
NOAC
CORRECTED NOA E-MAILED
01/01/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/29/2021
EX1G
SOU EXTENSION 1 GRANTED
12/28/2021
DPCC
DIVISIONAL PROCESSING COMPLETE
12/28/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
12/20/2021
EXT1
SOU EXTENSION 1 FILED
12/08/2021
DRRR
DIVISIONAL REQUEST RECEIVED
12/08/2021
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
12/08/2021
EEXT
SOU TEAS EXTENSION RECEIVED
12/08/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/22/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/27/2021
PUBO
PUBLISHED FOR OPPOSITION
04/27/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/07/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/25/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/24/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/24/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/24/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/09/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/09/2021
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
02/09/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/09/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/09/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/09/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/29/2020
GNRT
NON-FINAL ACTION E-MAILED
09/29/2020
CNRT
NON-FINAL ACTION WRITTEN
09/29/2020
DOCK
ASSIGNED TO EXAMINER
09/24/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/21/2020
NWAP
NEW APPLICATION ENTERED
06/26/2020
Continuous trademark protection
Get notified about every new filing that threatens TALLAC THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.